AssessmentsLysosomal storage disorders: Pathology review
USMLE® Step 1 style questions USMLE
A 3-year-old boy is being evaluated for developmental delay. He recently learned to sit up on his own; however, he is unable to stand up without support. His past medical history is significant for recurrent upper respiratory infections. His family is of Ashkenazi Jewish descent. Physical examination shows coarse facial features, kyphoscoliosis, and restricted joint mobility. Abdominal examination reveals hepatosplenomegaly. Ophthalmic examination reveals corneal clouding. A genetic condition is suspected. Which of the following intracellular processes are defective considering the most likely diagnosis?
Content Reviewers:Antonella Melani, MD
At the pediatric clinic, Abigail, a 5-month-old girl of Ashkenazi Jewish descent, is brought in by her parents because of recurring episodes of seizures, which started about a month ago.
Her parents have also noticed that Abigail startles easily at loud noises.
Physical examination reveals a low muscle tone with exaggerated reflexes.
Upon palpation of the abdomen, the liver and spleen are of normal size.
On ophthalmologic examination, a cherry red spot is found on the maculae of both eyes.
Next in the clinic, there’s 2-year-old Harry.
According to his mother, he recently stopped walking and speaking in sentences, and instead started crawling and babbling again.
On further questioning, his mother mentions that Harry seems to have a hard time sitting still and often shows aggressive behavior.
Physical examination reveals a prominent forehead, a nose with a flattened bridge and flared nostrils, an enlarged tongue, and thickened lips.
On ophthalmologic examination, no corneal clouding is observed.
Based on the initial presentation, both Abigail and Harry seem to have some form of lysosomal storage disorder.
These are a group of inherited metabolic disorders that result in the inability to break down certain substances in lysosomes, causing them to build up, and ultimately leading to cell damage and death.
Finally, there’s also mucolipidoses, which are caused by the accumulation of both sphingolipids and mucopolysaccharides
Okay, let’s start with sphingolipidoses!
Gaucher disease is the most common lysosomal storage disorder.
It is caused by a mutation in the GBA gene, which codes for the enzyme glucocerebrosidase, also known as beta-glucosidase.
For your exams, remember that Gaucher disease is autosomal recessive, meaning that an individual needs to inherit two copies of the mutated gene, one from each parent, to develop the condition.
Another thing to note is that Gaucher disease is more common in those of Ashkenazi Jewish heritage.
Now, glucocerebroside is a glycolipid that's included in the membrane of many different cells.
When these cells become old or damaged, they are often engulfed by macrophages, and digested in their lysosomes.
That’s where glucocerebrosidase breaks down glucocerebroside.
In Gaucher disease, glucocerebroside can’t be broken down, so it accumulates inside the lysosomes of macrophages.
These macrophages are called Gaucher cells and can build up in multiple organs and tissues, including the bone marrow, liver, and spleen.
And that’s a high yield fact!
Signs and symptoms vary depending on the tissue affected.
So, if that's the bone marrow, there can be anemia with fatigue, and leukopenia with increased susceptibility to infections.
Bone infarctions can also be caused by reduced blood flow to part of the bone, and can manifest as a painful “bone crisis” or result in physical deformity and avascular necrosis, or death of bone tissue, mostly involving the femur.
These individuals may also be more susceptible to fractures due to osteoporosis.
For your exams, another extremely high yield finding is hepatosplenomegaly, meaning that both the liver and spleen can become enlarged.
If glucocerebroside builds up in the brain, neurological symptoms can also appear, including loss of motor skills, hypotonia or decreased muscle tone, muscle spasms, seizures, and dysphagia or trouble swallowing.
Over time, this can progress to severe breathing and feeding difficulties, which, if left untreated, can progress to death within the first few years of life.
Diagnosis of Gaucher disease relies on measuring glucocerebrosidase enzyme activity in white blood cells, as well as genetic testing, to look for mutations in the GBA gene.
A high yield fact is that, on a tissue biopsy, Gaucher cells have a characteristic lipid-laden, or “fatty” appearance, similar to “crumpled tissue-paper.”
Treatment depends on the severity of the condition.
Symptoms can be managed with supportive therapy.
In addition, some individuals can get enzyme replacement therapy with a synthetic form of glucocerebrosidase, as well as substrate reduction therapy designed to block the production of glucocerebroside.
This results in hexosaminidase A, or HEX-A deficiency, which normally breaks down a GM2 ganglioside.
GM2 is found mainly in neurons, so when it builds up inside lysosomes, it results in progressive neurodegeneration.
For your exams, keep in mind that Tay-Sachs disease is also more common in those of Ashkenazi Jewish heritage.
Symptoms typically begin between 2 and 6 months of age and include progressive loss of motor and cognitive skills, along with hypotonia or decreased muscle tone, hyperreflexia, or abnormally increased reflexes, seizures, hyperacusis, or increased sensitivity to normal sounds, as well as feeding problems and vision loss.
What’s extremely important to remember is that GM2 can also build up in the retinal cells around the central macular area, causing a “cherry red spot” in the macula of the eye that can be seen with fundoscopy during an ophthalmologic examination.
Diagnosis of TSD is done by determining the activity of HEX-A in serum, leukocytes, tears, or any other body tissue, as well as genetic testing to look for mutations in the HEX-A GBA gene.
On histologic exam, neurons are distended with cytoplasmic vacuoles due to lysosomes filled with GM2, which give a characteristic onion skin appearance.
Treatment involves supportive care to manage symptoms.
Moving on to Fabry disease, this is caused by a mutation in the GLA gene that codes for alpha galactosidase A.
For your exams, remember that this is an X-linked recessive disorder, which means that all carrier males develop the disease because they have only one X chromosome and thus one GLA gene available.
On the other hand, females have two X chromosomes, so even if they have a defective GLA gene on one chromosome, they still have another functional one.
Now, alpha galactosidase A normally breaks down a sphingolipid called ceramide trihexoside, otherwise known as globotriaosylceramide or GL3 for short.
Without alpha galactosidase A, GL3 builds up in the lysosomes of endothelial cells lining blood vessels, as well as cells of the peripheral nervous systems, kidney, and heart cells.
Symptoms start in childhood and include a classic triad of peripheral neuropathy, hypohidrosis, and angiokeratomas.
Peripheral neuropathy typically manifests as burning, tingling, prickling, and pain in the hands and feet, and is frequently triggered by exercise, fatigue, stress, or illness.
Hypohidrosis means there’s a gradual decrease of sweating, which may progress to anhidrosis or an entire lack of sweating.
And angiokeratomas are small reddish-purple rashes that usually appear around the lower abdomen and “bathing trunk” region of the body.
A slit lamp eye exam might also reveal a whorl-like pattern of brown or gray corneal opacities, called cornea verticillata, which results from GL3 buildup in the cornea, but remember that it doesn’t typically affect vision.
Diagnosis of Fabry disease starts with blood tests showing low alpha galactosidase A levels, and is confirmed via genetic testing of the GLA gene.
Treatment options include enzyme replacement therapy with a synthetic alpha galactosidase A, or chaperone therapy with migalastat to help enhance residual enzyme activity.
Another sphingolipidoses is Krabbe disease, which originates from a mutation in the GALC gene, resulting in a deficiency of the enzyme galactocerebrosidase, also known as galactosylceramidase.
Normally, galactocerebrosidase breaks down galactosylceramides, such as galactocerebroside and galactosylsphingosine, also known as psychosine.
The most important thing to remember for your exams is that demyelination occurs both in the central as well as the peripheral nervous system.
Galactosylceramides can also accumulate inside macrophages, which become these gigantic, multinucleated macrophages called globoid cells that move in to clear out the damaged glial cells.
And these globoid cells are a classic finding in Krabbe disease.
Symptoms typically begin before 6 months of age.
Common symptoms of central nervous system demyelination include muscle stiffness, seizures, optic atrophy with visual disturbances, and developmental delay with difficulty in speaking, walking, or swallowing; while symptoms of peripheral nervous system demyelination may include loss of sensation in the extremities, along with hyporeflexia or diminished deep tendon reflexes.
Unfortunately, most infants die by the age of two.
Diagnosis is based on measuring the activity of galactocerebroside in leukocytes, along with genetic testing to look for mutations in the GALC gene.
There’s no cure for Krabbe disease, so treatment is mainly supportive.
Next is metachromatic leukodystrophy or MLD, which is an autosomal recessive disorder caused by a mutation in the ARSA gene, which codes for arylsulfatase A.
This enzyme normally breaks down cerebroside sulfate, so without it, sulfatide accumulates in neurons and myelin-producing cells of the central and peripheral nervous system, resulting in demyelination.
What’s important to remember here is that symptoms vary by the age of onset.
So, there’s a late infantile form, where symptoms develop within the first three years of life, and include severe muscle weakness, difficulty walking, irritability, and developmental delay, meaning a delay in reaching certain developmental milestones.
In the juvenile form, symptoms usually develop between the age of 4 and adolescence, which is around 12 and 14 years of age, and include behavioral changes and decreased ability in school.
- "Robbins Basic Pathology" Elsevier (2017)
- "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
- "Andrews' Diseases of the Skin" Saunders (2006)
- "Gaucher Disease: Clinical, Biological and Therapeutic Aspects" Pathobiology (2015)
- "Molecular Medicine" John Wiley & Sons (2016)
- "Disorders of Lipid Metabolism" Springer Science & Business Media (2012)
- "Andrews' Diseases of the Skin" Saunders (2006)
- "Laboratory diagnosis of Niemann–Pick disease type C: The filipin staining test" Methods in Cell Biology (2015)
- "Mucolipidosis II: a single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (GNPTAB) in a French Canadian founder population" Clinical Genetics (2008)